Edesa Biotech (NASDAQ: EDSA) CEO receives 5,324 restricted share units

Rhea-AI Filing Summary

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. Chief Executive Officer and 10% owner Pardeep Nijhawan received a grant of 5,324 restricted share units on 2026-08-03, vesting in full upon grant under the 2019 Equity Incentive Compensation Plan. After this award, he directly holds 893,386 common shares, plus additional indirect holdings through affiliated entities and a family trust, for which he disclaims beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

Net Buyer: 5,324 shares

Net Buy 5 txns

Insider Nijhawan Pardeep

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	5,324	$0.00	$0.00
holding	Common Shares F2	--	--	--
holding	Common Shares F3	--	--	--
holding	Common Shares F2	--	--	--
holding	Common Shares F2	--	--	--

Holdings After Transaction: Common Shares — 893,386 shares (Direct); Common Shares — 402,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation); Common Shares — 32,609 shares (Indirect, Held by The New Nijhawan Family Trust 2015); Common Shares — 32,013 shares (Indirect, Held by The Digestive Health Clinic Inc.); Common Shares — 53,104 shares (Indirect, Held by 1968160Ontario Inc.)

Footnotes (3)

1. F1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
2. F2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
3. F3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

Restricted share units granted: 5,324 units Direct common shares held: 893,386 shares Indirect shares via Pardeep Nijhawan Medicine Professional Corporation: 402,702 shares +3 more

6 metrics

Restricted share units granted 5,324 units Grant to CEO Pardeep Nijhawan on 2026-08-03

Direct common shares held 893,386 shares Direct holdings after the reported award

Indirect shares via Pardeep Nijhawan Medicine Professional Corporation 402,702 shares Indirect holdings; beneficial ownership disclaimed except for pecuniary interest

Indirect shares via The New Nijhawan Family Trust 2015 32,609 shares Trust holdings; beneficial ownership disclaimed except for pecuniary interest

Indirect shares via The Digestive Health Clinic Inc. 32,013 shares Indirect holdings; entity wholly owned by reporting person

Indirect shares via 1968160 Ontario Inc. 53,104 shares Indirect holdings; entity wholly owned by reporting person

Key Terms

restricted share units, 2019 Equity Incentive Compensation Plan, pecuniary interest, beneficial ownership

4 terms

restricted share units financial

"Reflects a grant of restricted share units, which vested in full upon grant"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Equity Incentive Compensation Plan financial

"pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

pecuniary interest financial

"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest"

beneficial ownership financial

"disclaims beneficial ownership of these securities except to the extent"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 05:02 PM Accepted by SEC EDGAR 08/04/2026 - 05:02 PM Learn about SEC filing dates

FAQ

What insider transaction did Edesa Biotech (EDSA) report for CEO Pardeep Nijhawan?

Edesa Biotech reported that CEO Pardeep Nijhawan received a grant of 5,324 restricted share units on 2026-08-03. The award vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan and is reflected as an acquisition of common shares.

How many Edesa Biotech (EDSA) shares does Pardeep Nijhawan hold directly after the grant?

Following the restricted share unit grant, Pardeep Nijhawan’s reported direct holdings total 893,386 common shares of Edesa Biotech. This figure represents his direct ownership position as reported in the Form 4 for the transaction dated 2026-08-03.

Were the Edesa Biotech (EDSA) restricted share units to the CEO immediately vested?

Yes. The filing states the 5,324 restricted share units granted to CEO Pardeep Nijhawan vested in full upon grant. The grant was made pursuant to Edesa Biotech’s 2019 Equity Incentive Compensation Plan and is treated as an immediate, fully vested equity award.

What indirect Edesa Biotech (EDSA) holdings are associated with entities related to Pardeep Nijhawan?

Entities wholly owned by the reporting person hold 402,702, 32,013 and 53,104 common shares, and a family trust holds 32,609 shares. Nijhawan disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in each entity.

Under which equity plan were the Edesa Biotech (EDSA) restricted units granted to the CEO?

The 5,324 restricted share units granted to CEO Pardeep Nijhawan were issued under Edesa Biotech’s 2019 Equity Incentive Compensation Plan. The filing notes that these units vested in full upon grant pursuant to this equity incentive program.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nijhawan Pardeep

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM L3R 5H6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/03/2026		A		5,324(1)	A	$0(1)	893,386	D
Common Shares								402,702	I	Held by Pardeep Nijhawan Medicine Professional Corporation(2)
Common Shares								32,609	I	Held by The New Nijhawan Family Trust 2015(3)
Common Shares								32,013	I	Held by The Digestive Health Clinic Inc.(2)
Common Shares								53,104	I	Held by 1968160Ontario Inc.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)